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57 ABSTRACT 
The present invention is related to a novel class of decar 
boxylase enzyme inhibitors consisting of O-oxiranyl amino 
acids and derivatives thereof and a method of synthesizing 
Such compounds. 
8 Claims, No Drawings 
  
5,705,660 
1. 
METHOD FOR THE SYNTHESS OF O 
OXRANYL AMNO ACDS 
GOVERNMENT RIGHTS 
The chemistry described in this application was not 
carried out under any grant or contract. However, it is the 
subject of pending grant applications at the NIH (No. 
1R29CA62034-01A1) and at the American Cancer Society 
(No. JFRA C-75777). 
A portion of the disclosure of this patent document 
contains material which is subject to copyright protection. 
The copyright owner has no objection to the facsimile 
reproduction by anyone of the patent document or the patent 
disclosure, as it appears in the Patent and Trademark Office 
patent file or records, but otherwise reserves all copyright 
rights whatsoever. 
CROSS REFERENCES 
1. Related Applications 
The present application is an original patent application 
and is currently not known to be related to any co-owned and 
co-pending application. 
TECHNICAL FIELD 
The invention describes (1) O-amino acids bearing an 
oxirane ring on the alpha carbon in place of the O-proton and 
(2) a method for synthesizing such amino acid derivatives. 
The object of this invention is to provide new mechanism 
based inhibitors for enzymes of the amino acid decarboxy 
lase class which cause inactivation via an enzyme catalyzed 
decarboxylation/ring opening sequence. The crucial ring 
opening step is to be greatly facilitated by (1) hydrogen 
bonding between the epoxide oxygen and the catalytically 
essential enzymatic general acid; and (2) relief of ring strain. 
Neither of these features have been incorporated into pre 
viously described amino acid decarboxylase inhibitors. Both 
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2 
are expected to lead to potent, specific and stringently 
mechanism-based inhibition. 
BACKGROUND OF THE INVENTION 
a. Mechanism of Inhibition 
The class of enzymes known as amine acid decarboxy 
lases (DC's) is of great interest from both a mechanistic and 
a therapeutic point of view. Mechanistically, this enzymatic 
family presents a curious dichotomy. Nature has chosen two 
very different co-factors to facilitate cleavage of the CCO 
bond. Pyridoxal phosphate is used by the vast majority of 
amino acid decarboxylases studied to date. However, some 
enzymes, such as S-adenosylmethionine decarboxylase 
(SAM DC), use pyruvamide to achieve the same task. It is 
generally accepted that both cofactors form Schiff bases 
with the C-amino group of substrate and act as electron 
sinks, providing for delocalization of the negative charge in 
the nascent o-carbanion formed upon enzymatic decarboxy 
lation. Overall, each catalyzes the net loss of CO2 from, and 
addition of a proton to, the o-carbon. With the exception of 
meso-diaminopimelate decarboxylase, all amino acid decar 
boxylases studied perform this sequence with retention of 
configuration. It is also noteworthy that while a few irre 
versible inhibitors have been developed for pyruvamide 
dependent decarboxylases (e.g. SAM DC), these inhibitors 
lack carboxyl groups. Decarboxylation-dependent irrevers 
ible inhibitors for pyruvamide-dependent decarboxylases 
have not yet been developed. 
In seeking to develop irreversible, enzyme-activated 
inhibitors, the generalstrategy has been to divert the nascent 
O-carbanion from O-protonation (i.e. turnover) in one of two 
ways: (1) by placing a leaving group (typically fluoride or 
chloride) at the B-carbon (o-halogenmethylamino acids); or (2) by placing a t-system adjacent to the carbanion (o-vinyl, 
ot-ethynyl and ol-allenyl amino acids), The most important 
members of these inhibitor classes are collected in Table 1 
(below). 
TABLE 1. 
Known Mechanism-Based Inhibitors of Amino Acid Decarboxylases 
Enzyme Enzyme Comm. No. Inhibitor(s) Potential Application 
L-DOPA E.C. 4.1.1.28 OH antihypertensive, 
Decarboxylase -- Parkinson's disease 
R NH (DOPA comb, therapy) 
OH 
R = vinyl, ethynyl, allenyl, CFH, CFH, 
CHFCI(m-tyr.) 
L-Ornithine E.C. 4.1.1.17 -- antineoplastic, treatment 
Decarboxylase R. NH + of trypanosomiasis and 
or-NuNH pneumonia 
R = vinyl, ethynyl, CFH, CFH CHFCl 
S-Adenosyl- E.C. 4.1.1.50 Me antineoplastic, treatment 
Methionine of trypanosomiasis 
Decarboxylase HoN-1 FN N+ 
(Pyruvamide) H O Ad 
HO OH 
L-Lysine E.C. 4.1.1.18 -- antimycoplasmic 
Decarboxylase HFC NH 
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TABLE 1-continued 
Known Mechanisin-Based Inhibitors of Amino Acid Decarboxylases 
Enzyme Enzyme Comm. No. Inhibitor(s) Potential Application 
Listidine E.C. 4.1.1.22 N antihistamine, 
Decarboxylase HFC NH3 / y antineoplastic 
pyruvamide) N 
H 
L-Arginine B.C. 4.1.1.19 H antibiotic, 
Decarboxylase RNH3 -- antiproliferative 2<-Nu N-NH. OC na 
NH 
R = CFH CF.H 
L-Ghutamate E.C. 4.1.1.15 investigative tool; 
Decarboxylase R, NH3 reduction of brain GABA 
R = vinyl, CHFC CO2 
levels 
o-Allenic-DOPA is a more effective inhibitor (shortert-2, 
more complete inactivation) than either o-vinyl- or 
ot-ethylyl-DOPA, although all three inactivate DOPA DC. 
This result shows that substitution of a three-carbon unit in 
place of the o-proton is quite tolerable, at least for DOPA 
DC 
The stereospecificity of inhibition has been studied for 
several of the O-halogenmethyl amino acids and is highly 
variable. For ofluoromethyl DOPA, only the expected (S)- 
antipode inhibits DOPA DC. But for 
ot-fluoromethylhistamine the unexpected (S)-antipode is the 
more potent inhibitor of histidine D.C. For 
o-chlorofluoromethylornithine, all four possible stereoiso 
mers inreversibly inhibit ornithine DC, all with t-2's 
between 2 and 4 minutes. The enantiospecificity of inhibi 
tion of the o-vinyl amino acids has yet to be determined. 
The prior art discloses only three labeling studies involv 
ing irreversible inhibitors for amino acid decarboxylases in 
25 
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which the chemical nature of the covalent enzyme-inhibitor 
or cofactor-inhibitor adduct has been investigated. 
Glutamate decarboxylase inactivation by L-serine O-sulfate 
represents the original case in which Metzler put forth his 
enamine mechanism.(Likos, J. J.; Ueno, H.; Feldhaus, R. 
W.; Metzler, D. E. "A Novel Reaction of the Coenzyme of 
Glutamate Decarboxylase with L-Serine O-Sulfate." Bio 
chemistry 1984, 23:5188-5194). However, this inhibitor is 
not stringently mechanism-based as it functions via enzyme 
catalyzed B-elimination rather than decarboxylation. On the 
other hand, B-fluoromethylhistidine is a good example of a 
mechanism-based decarboxylase inhibitor that also appar 
ently follows a Metzler enamine mechanism (See Scheme 1 
shown below).(Hayashi, H.; Tanase, S.; Snell, E. E. "Pyri 
doxal 5'-Phosphate -dependent Histidine Decarboxylase; 
Inactivation by ot-Fluoromethylhistidine." J. Biol. Chem. 
1986, 261, 11003-11009). 
Scheme 1 
Metzler Enamine Mechansim 
Proposed Mechanism of Histidine Decarboxylase Inactivation by C-Fluoromethylhistidine 
HN 21 HN 21 
HN1 Enz 
CO2 F- - 
-> rts Ser's -Ge. 
OPO2 "O OPO2- -O 21 OPO2 
5 1 Me N, 2 Me + 3 
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-continued 
Scheme 1 
Metzler Enamine Mechansin 
sed. Mechanism of Histidine Decarboxylase Enactivation by ot-Fluoromethylhistidine 
The postulated mechanism of action of 
o-fluoromethylhistidine involves enzyme-catalyzed decar 
boxylation followed by 3-fluoride-elimination. Transaldimi 
nation with an enzymatic lysine residue apparently ensues, 
leading to release of enamine 4. Nucleophilic attack of this 
enamine upon C-4 of the lysylpyridoximine results in the 
formation of a ternary enzyme-cofactor-inhibitor adduct 5. 
However, 5 can breakdown via a retro-Michael addition to 
release the enzymatic lysine residue and give a binary 
cofactor-inhibitor adduct 6. In certain cases binary adducts 
of this type (or the corresponding ketones) are released from 
the enzyme. In this case, the binary adduct is apparently 
intercepted via Michael addition of serine-322 in the wild 
type enzyme. However, Snell's group has shown that the 
corresponding Ser-Ala322 mutant is also essentially irre 
versibly inactivated by O-fluoromethylhistidine. They pro 
pose avid noncovalent binding of the pyridoxylidene imine 
6 (or the corresponding ketone) to the enzyme to account for 
this result. Other (non-decarboxylating) PLP-linked 
enzymes, for which evidence in support of a Metzler enam 
25 
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/F N 
21 
ea 
21 
N 6 M N 
H H 
Binary Cofactor-Inhibitor Adduct Ternary Enz.-Cofactor 
(tightly bound in the absence of Inhibitor Adduct 
Ser-322) 
ine mechanism has been obtained, include aspartate ami 
notransferase (serine O-sulfate), ornithine aminotransferase (4-aminohex-5-ynoate), Y-aminobutyrate transaminase 
(4-amino-5-fluoropentanoate and 4-aminohex-5-enoate), 
and alanine racemase (B-fluoroalanine, B-chloroalanine and 
O-acetylserine). 
In the case of ornithine decarboxylase inhibition by 
difluoromethylornithine (DFMO), labeling studies supporta 
Michael addition-elimination pathway (See Scheme 2 
shown below) (Poulin, R.; Lu, L.; Ackermann, B.; Bey, P.; 
Pegg, A. E., "Mechanism of the Irreversible Inactivation of 
Mouse Ornithine De carboxylase by 
o-Difluoromethylomithine." J. Biol Chem. 1992, 265, 
150-158). The trapped enzyme nucleophile in this case is a 
cysteine residue. A related Michael addition-elimination, in 
which lysine-38 is the enzyme nucleophile, appears to be 
operative in the inhibition of alanine racemase by 
B-trifluoroalanine (Faraci, W. S.; Walsh, C.T., "Mechanism 
of Inactivation of Alanine Racemase by B,B,3- 
Trifluoroalanine.” Biochemistry 1989, 28:431–437). 
Scheme 2 
Michael Addition-Elimination Mechanism 
Proposed Mechanism of Ornithine Decartboxylase Inactivation by co-difluoromethylornithine 
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Scheme 2 
Michael Addition-Elimination Mechanism 
Mechanism of Ornithine Decarboxylase inactivation by o-difluoromethylornithine 
-- -- 
H H 
F Enz f E 
its 1 2 s1 A. 
+N +N 
H1 N E. r 
D EnzN=Pyr 
21 OPO2- O 1m OPO2- O 21 OPO2 
a ! S a ! 
Me N O Me N 11 Me N 12 
H H H 
Enz 
s1 Srana 
s NaBH4 En-S Enz Ge. H s1 H s? G A. cy 
21 NS NH NH NH. 
HN HN 
-- 
13 14 15 16 
b. Therapeutic Potential. 30 
From a medicinal point of view, several enzymes in this o: Co. 
class are very important targets for the development of R NH R NH 
specific inhibitors. DOPA decarboxylase is the target of the H O O H 
important commercial drug O-methyl-DOPA used to treat 
hypertension. Peripheral DOPA DC inhibitors are used in as 
combination therapy with L-DOPA for the treatment of - 
Parkinsonism. Inhibitors of lysine DC are potential anti- E-oxiranyl Iriranyl 
mycoplasmic agents. As arginine DC is found in bacterial, ac Oc 
but not in mammalian systems, arginine DC inhibitors are CO CO2 
potential antibiotics. Inhibitors of histidine DC, ornithine to HN-R R--NH, 
DC and SAM DC all have potential as antitumor agents. In 3 
particular, the latter two enzymes control flux through the O H H O 
polyamine pathway. They are induced in response to various 
trophic influences and are essential for rapid cell prolifera 
tion. Indeed, inhibitors of these enzymes have proven to be as D-erythro-c-oxiranyl D-threo-o-oxiranyl 
potent antiproliferative agents in tissue culture. A SAM DC 
inhibitor cures African sleeping sickness in mice and 
o-difluoromethylornithine is effective against the microor 
ganism that produces pneumonia in AIDS patients. 
However, the effectiveness of these compounds as drugs is 
often compromised by compensatory mechanisms triggered 
by tumor cells (i.e.ornithine DC gene amplification or 
replacement of putrescine (ornithine DC product) with 
cadaverine (lysine DC product). This has stimulated the 
development of SAM DC inhibitors as potential 
antineoplastics, to be used in combination with ornithine DC 
inactivators. But most importantly, the reality of such tumor 
cell compensatory mechanisms underlines the need to 
develop DC inhibitors of fundamentally new structural 
classes. 
BRIEF SUMMARY OF THE INVENTION 
The present invention provides a new class of irreversible 
inhibitors for amino acid decarboxylases in which the 
o-proton is formally replaced with an oxirane ring. This 
design introduces a new stereocenter and so both erythro and 
threo diastereomers, as defined below are possible. 
50 
55 
65 
amino acid amino acid 
Synthesis involves the formal epoxidation of o-vinyl 
amino acids to yield ot-oxiranyl amino acids via a three to 
five step process wherein O-vinyl amino acids are synthetic 
precursors. Several of these precursors have been shown to 
be irreversible inhibitors of the corresponding decarboxy 
lases. Racemic O-vinyl amino acids are available from the 
corresponding amino acids. See Berkowitz and Pedersen, 
"Formal ot-Vinylation of Amino Acids. Use of a New 
Benzeneselenolate Equivalent,” Journal of Organic Chem 
istry 58:6966-6975 (1993) and references cited therein. 
The conversion of these o-vinyl amino acids to 
Ot-oxiranyl amino acids involves a new single step synthetic 
procedure wherein hydrogenolytically cleavable protecting 
groups are simultaneously installed on the amino, carboxyl 
and side chain (hydroxyl or amino) functional groups of the 
free vinyl amino acids. Using these fully protected vinyl 
amino acids, free ot-oxiranyl amino acids have been synthe 
sized. Due to diastereomer separation problems, two differ 
ent synthetic paths have been developed: (1) direct alkene 
epoxidation and (2) dihydroxylation, mesylation and dis 
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placement. In this way, the diastereomerically 
homogeneous, threo and erythro, O-Oxiranyl amino acids 
derived from valine, phenylalanine and alanine have been 
obtained. Other members of the o-oxiranyl class may be 
produced under a similar procedure. 
The process disclosed herein describes the first successful 
method of synthesizing fully deprotected o-oxiranyl amino 
acids. While U. Schollkopfreported in 1985 the synthesis of 
an O-amino acid ester, in which a phenyl-substituted oxirane 
ring replaced the alpha proton, Schökopf was unable to 
deprotect the carboxyl group without affecting the oxirane 
ring (Neubauer, H. J.; Baeze, J.; Freer, J. and Schöllkopf, 
"Asymmetric Synthesis of an Amino Acid Ester with a 
3,4-Epoxy Function (B, y-Epoxy Function) by the Bislactim 
Ether Method.” Liebigs Ann. Chem. 1508-1511 (1985). It is 
worthy to note that Schöllkopf commented, "3,4-Epoxy 
10 
15 
10 
amino acids or their esters are so far unknown. They are 
potential "suicide inhibitors' of pyridoxal phosphate depend 
ing enzymes. The problem, however, might be to hydrolyze 
the ester function . . . without touching the oxirane ring.” 
The present invention, among its other novel features and 
advantages, solves the problem identified by Schöllkopf by 
allowing both the simultaneous protection of the amino and 
carboxyl groups (as well as any hydroxyl or amino groups 
on the side chains) with hydrogenolytically removable pro 
tecting groups and the simultaneous removal of the protect 
ing groups without affecting the oxirane ring. Thus, the 
invention teaches the first process for producing fully depro 
tected ot-oxiranyl amino acids. 
The predicted mechanisms of enzyme inactivation by 
these compounds are depicted in Scheme 3 (below). 
Scheme 3: 
Proposed Decarboxylation/Ring Opening Mechanism: 
Ring Opening Driven by Hydrogen Bonding and Relief of Ring Strain 
BH 
- G R. H V A. 
-- 
H-N M W OH 
O 
A \ 
2 N OPO 
f 
H 
I 
(Common Intermediate) 
R H R Nu Ho PMP 
h 4. -- h H -- 
H R. Nu 
OH transfere H-N H CHOH ts H 
O H O CHOH 
/ \ I Me 
OPO2- N OPO2 
f+ 
H 
  
  
5,705,660 
11 12 
-continued 
Scheme 3: 
Proposed Decarboxylation/Ring Opening Mechanism: 
Ring Opening Driven by Hydrogen Bonding and Relief of Ring Strain 
Mechanism B: Cyclic N.O-Acetal Formation (Cofactor-Inhibitor Adduct) 
O K-1N HO 
H N O 
transfer Me / \ automerization 
N OPO2- HO N CHOPO2 
W+ 
H 1. 
Me N 
V 
Mechanian C: o?-Unsaturated minium Ion Formation/Michael Addition (Enzyme-inhibitor Adduct) 
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13 14 
-continued 
Scheme 3: 
Proposed Decarboxylation/Ring Opening Mechanism: 
Ring Opening Driven by Hydrogen Bonding and Relief of Ring Strain 
Mechanism D: Metzler Enanine Mechanism (Cofactor-Inhibitor Adduct) 
R 
-- 
ENH 
O 
-LysNH CHOH 
cHoH - Ge. / W 
Me 
N OPO2 
f a 
H 
X 
HO 
NH' NH 
Lys 
f R R 
H-N 
O O O SO 
/ V cho" / V cho Me Me 
2 N OPO N OPO 
f+ /+ 
H H 
XI X 
40 
Several features are noteworthy. First, these inhibitors 
have a two-step trigger. Analogous to the BY-unsaturated 
amino acids, they require both decarboxylation and 
protonation-precisely the two normal catalytic steps to 
inhibit. Unlike the fly-unsaturated amino acids, however, 
partial protonation in the form of a hydrogen bond from the 
requisite enzymatic general acid to the epoxide oxygen is 
possible. While not bound by any theory, protonation of the 
ring heteroatom is expected to facilitate ring opening, fol 
lowing enzymatic decarboxylation. This ring-opening step is 
thought to be thermodynamically driven by relief of ring 
strain 18 kcal/mol (for S) to 28 kcal/mol (for O and N). 
Further, this sequence is expected to lead to enzyme inac 
tivation as depicted in Scheme 3 (above). 
Four inactivation pathways have been conceived, all of 
which emanate from the common mechanistic intermediate 
I. The first of these, Mechanism A, is a direct Michael 
addition mechanism of the type postulated for both B.Y- 
unsaturated amino acids and ot-halogenmethyl amino acids. 
This mechanism is, of course, closely related to the Michael 
addition-elimination mechanism that appears to be operative 
in the case of DFMO and ot-trifluoromethylalanine (Scheme 
2, above). 
Mechanism D corresponds to the Metzler enamine 
mechanism (Scheme 1above) in the context of the present 
inhibitor design. Although unimportant to the enablement of 
the present invention, this mechanism of inhibition is 
45 
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unlikely because the enamine (VI) that would be released by 
transimination, bears a hydroxyl group to the nitrogen. This 
enamine is expected to readily eliminate a molecule of HO 
to generate an O.B unsaturated iminium ion in the active site (Mechanism C). Such a potent electrophile would likely be 
rapidly intercepted by an enzyme nucleophile in a Michael 
fashion. As this indirect Michael addition pathway is 
unavailable to the Ot-halogenmethyl amino acids, it repre 
sents a potentially important advantage of the inhibitors 
proposed herein. 
Another plausible inhibition pathway available to the 
O-oxiranyl inhibitors, referred to herein as Mechanism B, 
postulates that the hydroxyl group 6 to the imine carbon in 
intermediate I, cyclizes upon that carbon so as to form a 
six-membered N.O-acetal (Mechanism B). This pathway 
looks particularly advantageous for the L-threo 
stereoisomer, if the enzyme aligns the CCO bond with the 
pyridoximine TC-system above the si-face of the imine (as 
shown in Scheme 3). Conversely, if the enzyme aligns the 
CCO bond with the pyridoximine T-system above the 
re-face of the imine, the D-threo diastereomer would appear 
most likely to cyclize. Only for Mechanism B is there a 
compelling argument to favor one diastereomer (threo) over 
the other, a priori. Of course, the ability of the epoxide 
oxygen to hydrogen bond with the requisite enzymatic 
general acid is likely to be different for the two diastere 
omers and manifest itself in more efficient ring-opening, and 
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hence inactivation, for the favored diastereomer, Hence, for 
Mechanism.B, inhibition would result from the formation of 
tightly bound, noncovalent complex between the cofactor 
inhibitor adduct and the enzyme, analogous to the complex 
implicated in the inhibition of the Ser-Ala822 mutant of 
histidine DC by ot-fluoromethylhistidine. 
Schöllkopf raised concern about the possible instability of 
such ot-oxiranyl amino acids. Id. However, Sailer et al. have 
recently isolated a naturally occurring substituted ot-oxiranyl 
amino acid, flavovirin (Sailer, M.; Sasek, W.; Sejbal, J.; 
Budesinky, M.; Musilek, V. "Flavovirin-A New Antifungal 
Antibiotic Produced by the Pyrenomycete Melanconis fla 
vovirens.' J. Basic Microbiol 1989, 29:375-381). Flavovi 
rin is apparently stable to formic acid and to pyridine and 
was isolated as the free zwitterion. Interestingly, the com 
pound is an antibiotic and is highly active against yeasts. 
While mechanism elucidation may prove important in 
studies prompted by the present disclosure, such an under 
standing is not important to those seeking to practice the 
present invention where there is disclosed a process for 
producing O-oxiranyl amino acids, bearing side chains of 
proteinogenic amino acids, in a completely deprotected 
form. 
DETALEO DESCRIPTION 
a. O-Oxiranyl Amino Acids 
The present invention is related to compounds useful as 
decarboxylase enzyme inhibitors. These compounds have 
the general formula 
wherein R is selected from the side chains of any of the 
naturally occurring or synthetic proteinogenic amino acids 
commonly found or synthesized. R may be any straight or 
branched chain alkyl or aryl (including heterocyclic aryl) 
group and R may bear any of the following functional 
groups: ether, aldehyde, ketone, acetal, ketal, ester, amide, 
carbamate, nitrile, nitro, nitroso, phosphate, phosphonate, 
phosphinate, sulfone, sulfonate, sulfate or halide. R may also 
be the side chain of S-adenosylmethionine or its analog in 
which the sulfur atom is replaced by nitrogen. Examples of 
the naturally occurring proteinogenic amino acids are 
glycine, alanine, valine, leucine, isoleucine, phenlyalanine, 
tryptophan, serine, threonine, tyrosine, asparargine, 
glutamine, aspartic acid, glutamic acid, lysine, arginine, and 
histidine. Examples of other amino acids are m-tyrosine, 
DOPA, homoserine, ornithine, S-adenosylmethionine and 
the like. 
b. Process for the Synthesis of O-Oxiranyl Amino Acids 
(1) The Starting Material: ot-Vinyl-o-Amino Acids. 
O-Oxiranyl amino acids have been synthesized according 
to the present invention from the corresponding o-vinyl 
amino acids. It will be recognized by those skilled in the art 
that O-vinyl amino acids are valuable in and of themselves, 
as several are known irreversible decarboxylase inhibitors 
(Table 1, above). The o-vinylation of amino acid derived 
carbanions is perhaps the most direct synthetic route to these 
vinyl compounds. There are examples of this strategy in the 
literature, in which either phenylsulfonyl-activated Michael 
acceptors or o-silylated acetaldehydes serve as vinyl cation 
equivalents. Sawada, S.et al., J. Org. Chem 51: 3384-1986); 
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Huldrik, P. F. et al., J. Am. Chem. Soc. 103:625-53 (1981); 
Steglich, W. et al, Synthesis 1980, 481-83; Metcalf, B. W., 
et al., J. ChemSoc. Chem. Commun, 914-15 (1978) 
A conceptually different approach is discussed herein 
wherein a readily available electrophile, ethylene oxide, 
serves as the vinyl cation equivalent (Scheme 4, below). 
H R 
t O 2LDA (E) 
-- NHBZ -6E. G. 
HCO 
/ 2 r ... . PhSe 
O CHN 
NHB2 
O 
M 1. R R 
PhSe e O (i) O3, A (E) NH 
MeO2 NHB (ii)H3Ot O -- 
This chemistry has been applied to the synthesis of awinyl 
analogs of alanine, phenylalanine, valine, homoserine, 
omithine, lysine, arginine, histidine, aspartate and DOPA. 
The overall yield obtained for this sequence compares 
favorably to previously reported yields for the o-vinylation 
of protected amino acids and the scope is much broader. 
Furthermore, the use of ethylene oxide as vinyl cation 
equivalent eliminates the need to synthesize a vinyl cation 
equivalent. Hence, this procedure is arguably the method of 
choice for the formal oc-vinylation of amino acids.(Scheme 
4, above) 
Given the chemical versatility of the vinyl functionality, 
these derivatives may be viewed as simple building blocks 
for more complex, chain extended, (ot-branched amino 
acids. Such schemes require the presence of suitable pro 
tecting groups for the amino and carboxyl groups. 
(2) THE PROTECTION STEP:Simultaneous Amino 
(Cbz) and Carboxyl (Bn) Protection for o-Branched Amino 
Acids 
Our initial approach to Ot-oxiranyl amino acids was to 
epoxidize suitably protected O-vinyl amino acids. Consid 
ering the potential instability of these target molecules, we 
chose to employ protecting groups which could be removed 
under mild conditions. Specifically, we envisioned the use of 
hydrogenolytically removable benzyloxycarbonyl (Cbz) and 
benzyl ester (Bn) protecting groups for the amino and 
carboxyl groups, respectively. However, initial attempts to 
introduce the benzyloxycarbonyl (Cbz) group onto the 
O-amino group of free 0-vinyl amino acids using the usual 
Schotten-Baumann conditions (CbzCl, NaOH (aq)) met with 
little success. Under these conditions, benzyl chloroformate 
is apparently hydrolyzed faster than it reacts with the 
O-amino group of O-vinyl amino acids. Other established 
N-benzyloxycarbonylation reagents, including 
O-benzyloxycarbonyl-N-hydroxysuccinimide (Z-OSu) and 
p-(benyzyloxycarbonyloxy)-phenyldimethylsulfonium 
methylsulfate (Z-ODSP), also failed, presumably due to the 
sterically congested environment about the amino group. 
Indeed, the problems associated with amino group carbo 
nylation for O-branched amino acids are well known and 
have been described by others (Turk, J.; Panse, G. T.; 
Marshall, G. R. J. Org. Chem, 40:953-955 (1975)). 
In view of the report by Whitesides and coworkers that 
O-methyl amino acids could be N-chloroacetylated by 
refluxing with chloroacetyl chloride in acetonitrile 
(Chenault, H. K.; Dahmer, J.; Whitesides, G. M. J. Am. 
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Chem. Soc. 111:6354–6364 (1989)), and presuming that use 
of an organic solvent would prolong the lifetime of CbzClin 
the reaction mixture and thereby facilitate the desired 
N-benzyloxycarbonylation, we heated O-vinyl amino acids 
with CbzCl in a variety of polar organic solvents (CHCN, 
DMF, DMPU, HMPA, DMSO). The best results were 
obtained with CbzCl, NEt, and catalytic DMAP, in DMSO 
at 50° C. Under these conditions, provided that excess 
CbzCl was present, both the ot-amino (Cbz) and O-carboxyl 
(Bn) groups could be protected in a single step, in good yield 
(Table 2, below). Furthermore, amino (o-vinylornithine and 
o-vinylysine), and hydroxylic (o-vinyl-DOPA) side chains 
could also be protected as the corresponding carbamates or 
carbonates in the same pot, given sufficient CbzCl. (Table 2, 
below) 
10 
18 
those cases, an o-proton is always present, Thus Kim's 
procedure has not been applied to the simple esterification of 
(more hindered) N-protected O-branched O-amino acids. By 
contrast, this is the first report of the simultaneous conver 
sion of an amine to a carbamate (N-benzyloxycarbonylation) 
and an acid to an ester (benzyl esterification) of an o-amino 
acid in a single synthetic step. All of our examples are for 
Zwitterionic, free amino acids that are not soluble in CH2Cl2. 
Further, our procedure requires heating the amino acids in 
dimethylsulfoxide (DMSO) at 50° C. Many other solvents 
were examined and found to work much less well than 
DMSO or not at all. We believe the reason our procedure 
works better for o-vinyl o-amino acids than for usual 
o-amino acids (bearing an o-proton), even though the 
former have considerably more hindered carboxyl and 
TABLE 2 
Simultaneous Amino and Carboxyl Group Protection for c-Vinyl Amino Acids 
Series o-Vinyl Amino Acid Equiv, CbzCl Product Yield 
Alanine =. Me 3.5 Me 17 62% 
E) - O F BIO (E) NH (E) Bn NHCbz 
- 
O O 
Waline Me 3 Me 18 73% 
F, Me - Me (E)-O 3: (t) Bno. 2 NH NHCbz 
+ 
O O 
Phenylalanine 3 9 82% 
F. --, 
E) - O i) Bn(O (E) NH3 (t) NHCbz 
-- 
O O 
Ornithine NH3 5 NHCbz 20 62% 
s + 
- -, '7, 
it) - O F EBnO F (t) 5- 1 (E) Bn a. 
O O 
Lysine NH 5 NHCbz 21 60% 
3 
a 
-. (1) Bno, 2 (E) - O NH NHCbl 
2 
O 
O 
DOPA OH 8 O 22 47% 
o-K 
OBn 
== OH 
(E) - O F O NH - -, 
-- (E) BnO SO O NHCBE 
O BnO 
The benzyl esterification presumably proceeds via the 
mixed anhydride. This sort of esterification chemistry finds 
some analogy in the work of Kim Kim, S.; Lee, J. E.; Kim, 
Y.C., J. Org. Chem 50:560-565 (1985). However, there are 
significant differences between the two procedures. Kim et 
al. report the conversion of acids to esters only and all of 
their examples are for neutral acids that are soluble in 
methylene chloride (CHCl2) at 0°C. In all cases, if an 
amino group is present, it is protected, including several 
examples of N-protected o-amino acids. However, even in 
amino groups than the latter, is the greater solubility of 
60 o-vinyl amino acids in DMSO overo-unbranched O-amino 
65 
acids. 
The protection method described herein appears to be 
preparatively useful only for relatively hydrophobic amino 
acids, such as Ot-branched amino acids, presumably due to 
their greater solubility in DMSO. But it is precisely for 
o-branched amino acids, in which the amino group is 
particularly hindered, that this chemistry is most valuable. In 
support of this solubility argument, a qualitative correlation 
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between size of the alkyl chain and percent yield was 
observed. This is illustrated for several O-branched valine 
analogues in Scheme 5 (below). 
Scheme 5 
Me 
Me 10 
(t) OC NH (E) BnOC NHCbz 
-- 
compound 23 24 25 18 
15 
R H Me Et vinyl 
yield 21% 41% 54% 73% 
In summary, this is the first report of a one pot procedure 
for the protection of amino acids with both carbamate (amino group) and benzyl ester protecting groups. The 
procedure is most efficient for relatively hydrophobic, 
Ot-branched amino acids. The nature of the carbamate and 
ester protecting groups could presumably be changed by 
simply varying the alkyl chloroformate employed. 
Moreover, when combined with our O-vinylation 
methodology, this procedure provides a direct route from 
o-amino acids to their N-Cbz, benzyl ester protected, 
o-vinyl derivatives. These, in turn, are expected to find 
broad application as building blocks for novel o-branched 
amino acids. For instance, it may be possible to directly 
chain-extend and functionalize these with Heck chemistry, 
as was recently demonstrated for N-Cbz-vinylglycine. 
On the other hand, the N-Cbz-protected o-vinyl amino 
esters reported herein may be transformed into the corre 
sponding 0-formyl amino acids. For example, ozonolysis of 
3b proceeds smoothly to yield the protected, 
ot-formylphenylalanine, 12 (Scheme 6below). 
20 
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35 
Scheme 6 
H 40 
= o=4 
CHPh 0. CHPh (E) - Miss S (t) p Bn NHCOBn NHCOBN (94%) 19 26 45 
Olefination of such protected,0-formyl amino acids 
would provide a complementary strategy for branch exten 
sion. Indeed, modified Wittig olefinations of related 
carbamate-protected (o-amino aldehydes, derived from 
unbranched amino acids, as well as O-branched amino acids, 
are well known. For such applications, hydrogenolytically 
clearable protecting groups, such as those installed herein, 
are especially attractive, as they might be removed in the 
same operation in which the o-side chain is saturated. 
SPECIFC EXAMPLES OF PROTECTION STEP 
General. All general experimental procedures were as 
described previously in the applicants' article in Journal of 
Organic Chemistry, supra. The starting O-vinyl amino acids 
were synthesized as reported. See Table 2, supra. These 
procedures are ideal for our purposes, providing epoxidation 
substrates in one step from completely deprotected O-vinyl 
amino acids 
50 
55 
EXAMPLE NO. 1 
(E)-Benzyl N-Benzyloxycarbonyl-ol-vinylphenylalanine 
(19). To a suspension of (+)-vinylphenylalanine (560 mg. 
65 
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2.9 mmol), NE t (1.6 mL, 12 mmol) and 
4-dimethylaminopyridine (71 mg, 0.59 mmol) in dry DMSO 
(3 mL) at 10°C. was added benzyl chloroformate (1.9 mL, 
13 mmol), dropwise and with stirring. After being stirred for 
1.5 h at 50° C., the reaction mixture was diluted with EtOAc 
(150 mL) and extracted with NaHCO (aq, 50 mL). The 
organic layer was further extracted with 1N HCl (50 mL) 
and brine (50 mL). After drying (MgSO), the volatiles were 
evaporated in vacuo and the residue purified by flash SiO, 
chromatography (10% EtO-hexane) to give 19 (1.0 g, 82%) 
as a white solid: mp 68°-70° C.; H NMR (500 MHz, 
CDCl) 83.33 (d. J=13 Hz, 1 H); 3.62 (d, J=13 Hz, 1 H): 
5.10-5.25 (m, 4H); 5.27 (d, J=10 Hz, 1H);5.28 (d.J=17 Hz, 
1H); 5.68 (s, 1 H); 6.08 (dd, J-10, 17 Hz, 1 H); 6.90-6.91 (m. 2 H); 7.10–7.20 (m, 3 H); 7.26–7.43 (m. 10 H); "C 
NMR (125 MHz, CDC1,) 8 40.4, 65.1, 66.5, 67.8, 116.2, 
126.9, 128.1, 128.20, 128.23, 128.4, 128.5, 128.6, 130.0, 
130.3, 135.0, 135.4, 136.6, 136.8, 1544, 1712; IR (film) 
3420-3330, 1723 cm; HRMS (FAB, 3-NOBA) calcd for 
CHNONa (M+Na)" 438.1681, obsd 438.1685. Anal. 
Calcd for CHNO: C, 75.16; H, 6.07; N, 3.37. Found: C, 
74.98; H, 6.22; N, 3.37. 
Compounds 17, 18 and 20–25 were synthesized analo 
gously (all reaction times were 1.5-2 h), with the molar 
ratios of CbzCl and yields indicated in Table 2 (above) and 
Scheme 5 (above), and displayed the following spectral 
characteristics: 
EXAMPLE NO. 2 
(E)-Benzyl N-Benzyloxycarbonyl-ol-vinylalaninate (17). 
mp52°-54° C.; H NMR (300 MHz, CDC1) 81.69 (s.3 H); 
5.07 (s.2H);5.16 (s.2H); 5.22-5.25 (d, J=11 Hz, 1H);5.28 
(d, J-17 Hz, 1 H); 5.61 (s, 1H); 6,07 (dd, J=11, 17 Hz, 1 H); 
7.28-7.40 (m. 10 H); 'C NMR (75 MHz, CDCl)8 23.0, 
60.6, 66.6, 67.5, 115.7. 127.9, 128.0, 128.1, 128.3, 128.4, 
128.5, 135.4, 136.3, 137.6, 1546, 172.3; IR (film)3352, 
1716 cm; HRMS (FAB, 3-NOBA) calcd for CHNO (M--H)" 340.1549, obsd 340.1546. Anal. Calcd for 
CHNO: C, 70.78; H, 6.24; N, 4.12. Found: C, 70.79; H, 
6.34; N, 4.18. 
EXAMPLE NO. 3 
(+)-Benzyl N-Benzyloxycarbonyl-o-vinylvalinate (18). 
mp 62°-64° C.; H NMR (300 MHz, CDC) 80.85 (d, J-7 
Hz, 3 H); 0.86 (d. J=7 Hz, 3 H); 2.11-2.19 (m, 1H); 
4.96-5.30 (m, 7 H); 6.28 (dd, J-11, 17 Hz, 1 H); 7.26-7.40 (m. 10 H); 'CNMR (125 MHz, CDCI) 8 16.9, 17.5, 35.4, 
65.4, 66.9, 67.3, 115.5, 128.1, 128.2, 128.23, 128.4,128.46, 
128.5, 133.9, 135.6, 136.4, 155.0, 171.7; IR (film) 
3448-3258, 1727 cm; HRMS (FAB, 3-NOBA) calcd for 
CHNONa (M+Na)" 390.1681, obsd 390.1685. Anal. 
calcd for CHNO: C, 71.91; H, 6.86; N, 3.81. Found: C, 
72.14; H, 6.66; N, 3.91. 
EXAMPLE NO. 4 
(+)-Benzyl O.8-Bis(N-benzyloxycarbonyl)-o- 
vinylomithinate (20). "H NMR (300 MHz, CDC1) 8 
1.15-1.28 (m, 1 H), 1.36-1.49 (m, 1H), 1.98-2.10 (m, 1 H), 
2.28–2.41 (m, 1H), 3.03-3.15 (m, 2 H), 4.59–4.69 (m, 1 H), 
5.01-5.31 (m, 8 H), 5.82 (s, 1 H) 5.99 (dd, Je10, 17 Hz, 1 
H), 727-7.50 (m, 15 H); 'C NMR (125 MHz, CDC1)8 
24.2, 32.0, 40.5, 64.0, 66.6, 66.7, 67.8, 115.9, 128.1 (2 C), 
128.2, 128.3 (2 C), 128.4, 128.5 (2 C), 128.6, 128.7, 135.1, 
136.3, 136.6, 1542, 156.3, 171.7: IR (film) 3439-3277, 
1717 cm; HRMS (FAB, 3-NOBA) calcd for CHNO (M+H) 517.2338, obsd 517.2341. 
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EXAMPLE NO. 5 
(+)-Benzyl ol.e-Bis(N-benzyloxycarbonyl)-O- 
vinylysinate (21). 'HNMR (300 MHz, CDCl3) 80.93-1.02 
(m, 1 H), 1.19-1.45 (m, 3 H), 1.92-2.02 (m, IH), 2.24-2.34 
(m, 1 H), 3.01-3.10 (m, 2H), 4.69-473 (m, 1H), 5.00-5.27 
(m, 8 H), 5.87 (s, 1 H), 6.01 (dd, J-10, 17 Hz, 1 H), 
7.26 7.39 (m, 15 H); "CNMR (125 MHz, CDCl) 820.6, 
29.3, 34.5, 40.3, 64.2, 66.6, 66.7, 67.6, 115.5, 128.0, 128.1, 
128.3 (2 C), 128.4 (2 C), 128.5, 128.6 (2 C), 135.1, 136.3, 
136.5, 136.7, 1543, 1564, 171.8; IR (film) 34.13–3298, 
1716 cm; HRMS (FAB, 3-NOBA) calcd for CH3N2O6 
(M+H) 531.2495, obsd 531.2478. 
EXAMPLE NO. 6 
(+)-Tris(N.O.O'-benzyloxycarbonyl)-o-vinyl-DOPA, 
benzyl ester (22). H NMR (300 MHz, CDCl3) 83.34 (d. 
J=13 Hz, 1H); 3.64 (d, J-13 Hz, 1H);5.03-5.34 (m, 10 H); 
5.71 (s, 1 H); 5.99 (dd, J=10, 17 Hz, 1 H); 6.71-6.75 (m. 1 
H); 6.92-6.98 (m,3): 7.26-7.40 (m. 20 H); "CNMR (125 
MHz, CDC) & 39.4, 65.0, 66.7, 68.0, 70.5, 70.6, 1166, 
122.5, 124.6, 126.9, 128.07, 128.1, 128.2, 128.3, 128.4, 
128.45, 128.5, 128.57 (2 C), 128.61 (2 C), 128.64 (2 C), 
128.7 (2 C), 134.7, 1349,136.4, 141.3, 1419, 152.5, 152.6, 
154.5, 1707; ER (film) 3411 (br), 1767,1722 cm; MS (FAB, 3-NOBA/KCO) 754 (base peak) (M+K); HRMS (FAB, 3-NOBA) calcd for CHNO (M+H) 716.2496, 
obsd 716.2497. 
EXAMPLE NO. T. 
(E)-Benzyl N-benzyloxycarbonylvalinate (23) "H NMR 
(500MHz, CDC1): 80.84 (d, J-7 Hz, 3 H); 0.94 (d, J=7 Hz, 
3 H); 2.16-2.19 (m, 1 H); 4.34-4.36 (m. 1 H); 5.105.20(m, 
4H); 5.25-5.27 (m, 1 H); 7.30-7.38 (m, 10 H). 
EXAMPLE NO. 8 
(E)-Benzyl N-benzyloxycarbonyl-O-methylvalinate (24), 
From O-methylvaline: "H NMR (500 MHz, CDCla) 8 0.86 
(d, J=7 Hz, 3 H); 0.92 (d, J=7 Hz, 3 H); 1.58 (s, 3 H); 
2.102.14 (m, 1 H); 5.02-5.18 (m, 4 H); 5.32 (s, 1 H); 
7.27-7.38 (m, 10 H); "C NMR (125MHz, CDC)8 17.1, 
17.2, 18.7, 35.2, 66.6, 67.0, 69.7, 128.1,128.2, 128.3, 128.4, 
128.5, 128.54, 135.6, 136.3, 155.2, 173.5; IR (film) 
3417-3319, 1719 cm; HRMS (FAB, 3-NOBA) calcd for 
CHNO (M+H) 356.1862, obsd 356.1851. 
EXAMPLE NO. 9 
(E)-Benzyl N-Benzyloxycarbonyl-O-ethylvalinate (25). 
From ot-ethylvaline: "H NMR (500 MHz, CDC)ö 0.71 (t, 
J=7, 15 Hz, 3 H); O. 87 (d, 3 H, J=7 Hz); 0.93 (d, J-7 Hz, 
3 H); 1.95-2.02 (m, 1 H); 2.43 (app quintet, J-7 Hz, 1 H); 
2.50-2.60 (m, 1 H);5.03-5.09 (m, 2H);5.15-5.21 (m,2H); 
5.89 (s, 1 H); 7.28-7.35 (m, 10 H); C NMR (125 MHz, 
CDC) 89.4, 18.4, 18.5, 25.8, 34.9, 66.8, 68.1, 68.9, 128.5, 
128.7, 129.0, 129.1, 1292, 129.3, 135.8, 137.4, 1548, 
173.8; IR (film) 3425-3352, 1717 cm; HRMS (FAB, 
3-NOBA) calcd for CHNO (M+H)" 3702018, obsd 
370.2011. 
EXAMPLE NO. 10 
(E)-Benzyl(N-Benzvloxycarbonyl)-2-aminomalonate 
semialdehyde (26). Into a solution of 19 (25 mg, 60 mol) 
in CHCl (15 mL) at -78°C. was bubbled O. until a light 
blue color persisted. After reductive workup with MeS (1 
mL) at It for 2 h, the volatiles were evaporated. The residue 
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was partitioned between H.O. (20 mL) and EtOAC (2x20 
mL). The organic extracts were then dried (MgSO), filtered 
and concentrated to afford 26 (23 mg.94%): "H NMR (300 
MHz, CDC) 83.49 (d, J=14 Hz, 1 H); 3.57 (d, J-14 Hz, 
1H);5.07-5.24 (m, 4H); 5.79 (s, 1H); 6.79-6.82 (m.2 H); 
7.11-7.23 (m, 3 H); 7.26–7.44 (m, 10H);9.60 (s, 1 H); "C 
NMR (125 MHz, CDC) 837.9, 67.9, 69.2, 72.4, 128.0, 
128.9, 129,0, 1292, 129.3, 129.4, 129.5, 130.4, 130.6, 
1344, 135.0, 136.6, 155.7, 167.3, 193.3; IR (film) 
3444-3300, 1729 cm; HRMS (FAB, 3-NOBA) calcd for 
CHNONa (M+Na)" 440.1474, obsd 440.1479. 
(3) THE EPOXIDATION STEP:ALTERNATIVE PRO 
CEDURES 
The protected o-vinyl amino acids thereby obtained can 
be epoxidized with m-chloroperoxybenzoic acid (MCPBA) 
in CHCl2. The reaction shows little to no diastereoselec 
tivity (1-1.5:1 ratios). More importantly, separation by flash 
chromotography of the diastereomeric protected, O-Oxiranyl 
amino acids proved possible only for the valine-derived 
diastereomers. The alanine-derived diastereomers could be 
separated by HPLC. 
In the case of the diastereomeric 
o-oxiranylphenylalanines, however, HPLC with normal and 
reverse phase (C-18) columns and a variety of eluents failed 
to give separation.(Scheme 7, below) 
Scheme 7 
Epoxidation Step: 
O 
"...R MCPBA '...l. EBO f - Se Bn) (E) Bn CHC, 2 (E) Bn NHCBE 
O O 
17-19 (2 diastereomers) (1-1.5:1 ratio) 
Diastereomers 
R Yield Separable? 
27a,b CH T9% Yes 
(by HPLC only) 
28a,b CHCH.) 78% es 
29ab CHPh 81% No 
a Fe erythro; 
b = threo 
This led us to examine alternate procedures for synthe 
sizing o-oxiranyl amino acids via diastereomeric interme 
diates that might be more easily separated chromatographi 
cally. We have found that, in the case of phenylalanine, at 
least, the epoxides may be synthesized indirectly from the 
corresponding vic-diols. Most importantly, dihydroxylation 
of protected o-vinylphenylalanine leads to two diastereo 
meric vic-diols that are readily separated by flash silica gel 
chromatography: 
(A) DIRECTEPOXIDATION: 
In the direct epoxidation approach, the vinyl amino acids 
are epoxidized with m-chloroperoxybenzoic acid 
(MCPBA). The diastereomeric epoxides therby produced 
are sometimes easily separable (i.e. vaine), and sometimes 
essentially inseparable (i.e. phenylalanine) (Scheme 7, 
above) 
(B) INDIRECTEPOXIDATION 
To ensure that the erythro and threo diastereomers could 
be readily separated, a second, indirect epoxidation proce 
dure was also established. In this approach, the o-vinyl 
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amino acid is initially converted to the diasteromeric erythro 
and threo vicinal diols through the agency of osmium 
tetroxide. The diastereomeric vicinal diols are generally 
more easily separated by silica gel chromatography than the 
corresponding diastereomeric epoxides. Once the erythro 
and threo diastereomers have been separated, they are indi 
vidually transformed to the respective epoxides in two steps. 
Regiospecific mesylation of the less hindered primary 
hydroxyl group is achieved with methanesulfonyl chloride 
in pyridine-dichloromethane. This is followed by treatment 
with lithium diisopropylamide (LDA) in tetrahydrofuran, 
which gives the diastereomerically homogeneous epoxide. 
In the example given below, the otherwise essentially 
inseparable erythro and threo diastereomers of O-oxiranyl 
phenylalanine are obtained in diastereomerically homoge 
neous form by this procedure. (Scheme 8, below) 
Scheme 8: 
A Solution to the Diastereomer Separation Problem, 
o-Oriranyl Amino Acids from Vicinal-Diois 
echins OsO4 NMO 
R COBn , t-Bu H2 
R =Me 17 
Ris-Pr 18 
Rs.9n 19 
H OH OH OH H OH 
extin + (t)CbzNH s 
RN coBn RN coBn 
(separate by flash chromatography) 
(R = Me 45a (lactone) R=Me 30b 
R = i-Pr 31a R=i-Py 31b 
R=Bn. 32a Ric Bn 32b 
HO OH 
(ectone ME > 2 RN coBn 
R=Me 30b 
R = i-Pr 31a(b) 
R=Bn 32a(b) 
HO OMs 
t LDA (sches / Are Y R COBn 
R=Me 33b 
R=i-Pr 34a(b) 
R=Bn 35a(b) 
O 
(ECbzNH 
RN coBn 
R-Me 27b. 
R=i-Pr 28a0b) 
R=Bn 29a(b) 
(a = erythro; b. = threo) 
Each diastereomerically homogeneous diol in the valine 
and phenylalanine series has now been mesylated and 
cyclized to the corresponding protected, O-oxiranyl amino 
acid. In the alanine series, this sequence was carried out for 
the threo diastereomer only. The erythro diastereomer 30a 
lactionized to 45a at the stage of the dihydroxylation. 
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SPECIFIC EXAMPLES OF THE EPOX DATION 
STEP 
General Procedure A 
Benzyl N-Benzyloxycarbonyl-o'-oxiranylvalinate (+)- 
28a/(E)-28b). To a solution of (E)-18 (150 mg., 0.41 mmol)in 
CHCl (5 mL) at rt was added m-chloroperbenzoic acid 
(350 mg, 2.0 mmol). After 30 h., the reaction mixture was 
diluted with cold Et20 (50 mL), and washed successively 
with 10% Na2SO (aq, 30 mL) and NaHCO (aq, sat'd, 30 
mL). The organic layer was dried (MgSO4), filtered and 
concentrated. Flash chromatography (35% EtOAc/hexane) 
provided the two diastereomers: (E)-28a (oil): 48 mg (31%); 
IR (film) 3427-3303,1724 cm"; "H NMR (500 MHz, 
CDCl) 8099-1.01 (d, J-7 Hz, 3 H), 1.04-1.05 (d, J-7 Hz, 
3 H), 2.34-2.39 (m. 1 H), 2.67-2.68 (m. 1H), 2.74-2.75 (m, 
1H), 3.55 (s, 1H), 5.00-5.10 (m, 3 H), 5.11-5.21 (m, 2 H), 
7.32-7.39 (m, 10 H); C NMR (125 MHz, CDC1)8 17.5, 
17.6, 34.8, 44.8, 52.5, 63.9, 66.9, 67.3, 128.2, 128.3, 128.35, 
128.4, 128.5 (2 C), 128.6, 135.3, 155.2, 169.8; Anal. Calcd 
for CHNOs: C, 68.91; H, 6.57; N, 3.65. Found: C, 69.09; 
H, 6.54; N, 3.71, (E)28b (white solid): 74 mg (47%); mp 
74°-76° C.;IR (film)3410–3280, 1729 cm; "HNMR (500 
MHz, CDC) 8 0.97-0.99 (d, J=7 Hz, 3 H), 0.99-1.01 (d. 
J-7 Hz, 3 H), 2.65-2.68 (m, 2 H), 2.71-2.80 (m, 1 H), 3.57 
(s, 1 H), 5.02-5.07 (app t, J=12 Hz, 2 H), 5.14-5.21 (m, 3 
H), 7.29-7.40 (m. 10 H); 'C NMR (125 MHz, CDCl)8 
17.6 (2 C), 32.5, 45.0, 52.8, 64.7, 66.9, 67.5, 128.1, 128.2, 
128.4 (2 C), 128.5 (2 C), 135.2, 136.2, 155.2, 170.7; Anal. 
Calcd for CHNOs: C, 68.91; H, 6.57;N, 3.65. Found: C, 
68.81; H, 6.55; N, 3.65. 
Benzyl N-Benzyloxycarbonyl-O-oxiranylalaninate (E)- 
27a/(E)-27b). From (E)-17 (16.7 mg, 0.049 mmol), follow 
ing General Procedure A, was obtained a diastereomeric 
mixture of epoxides 137 mg, 79%; (E)-27a:(E)-27b (1:2.5)). 
Separation of these diastereomers was possible by HPLC 
isocratic elution with EtO/hexane/toluene (46:46:8)). (E)- 
27a(white solid): mp 85-87 C.; IR (film) 3407-3184, 
1731, 1718 cm; "HNMR (500 MHz, CDC1) & 1.59 (s.3 
H), 2.74-2.75 (m, 2 H), 3.37 (s, 1 H), 5.01-5.08 (m. 2 H), 
5.13-5.29(m, 3H), 7.30-7.41 (m, 10 H); 'C NMR (75 
MHz, CDCI) 820.7, 446,546, 58.5, 66.9, 67.5, 128.1 (2 
C), 128.2, 128.3, 128.5, 128.7, 135.3, 136.1, 155.0, 1712; 
Anal. Calcd for CHNO: C, 67.59; H, 5.96; N, 3.94. 
Found: C, 67.41; H, 6.06; N, 3.83. (E)-27b (white solid):mp 
86°-88° C.; IR (film) 3484-3296, 1734, 1717 cm; "H 
NMR (300 MHz, CDC1) 8 1.59 (s, 3 H), 2.70-2.73 (dd, 
J=34 Hz, 1 H), 2.79-2.83 (app t, J-4 Hz, 1 H), 3.46-3.48 
(dd, J-34 Hz, 1 H), 5.07 (s, 2 H), 5.16-5.24 (m.2 H), 5.31 (s, 1 H), 7.34-7.40 (m, 10 H); 'CNMR(75 MHz, CDC1,) 
8 19.2, 28.2, 44.3, 54.7, 66.9, 67.6, 128.0, 128.1,128.2, 
128.4, 128.5, 128.6, 135.29, 135.3, 155.5, 171.9; Anal. 
Calcd for CHNOs: C, 67.59; H, 5.96; N, 3.94. Found: C, 
67.45; H, 6.04; N, 3.85. 
Benzyl N-Benzyloxycarbonyl-o'-oxiranylphenylalaninate 
(E).29a/(E).29b). From (E)-19 (16.7 mg, 0.049 mmol), 
following General Procedure A, was obtained an inseparable 
diastereomeric mixture of epoxides 210 mg, 81%; (E)-29a: 
(E)-29b (1:1.5)). Spectral data for the individual diastere 
omers are tabulated below. 
General Procedure B 
Benzyl 2-Benzyl-2-benzyloxycarbamido-3,4- 
dihydroxybutanoate E(E)32a(E)-32b). To a solution ofCE)-19 (1.00g, 2.407 mmol) in THF (23 mL), containing 2-methyl 
2-propanol (1 mL) and H2O (0.6 mL) atrt were added, OsO, 
5,705,660 
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(18 mg 0.072 mmol) and 4-methylmorpholine-N-oxide 
(NMO)(366 mg, 3.13 mmol). After 17 h, Florisil (2 g) and 
NaHSO (1.4 g) were added and the resulting suspension 
stirred for 30 min. Following dilution with EtOAc and 
filtration (Celite), the diastereomeric diols were purified by 
SiO, chromatography (35% EtOAchexane): (E)-32a (wax): (657 mg, 61%); IR (film)3454-3279, 1732, 1689 cm '; 'H 
NMR (300 MHz, CDCl) 81.74-177 (m, 1 H), 3.10-3.15 
(d. J=14 Hz, 1 H), 3.39-3.45 (m, 1 H), 3.59-3.65 (m, 1 H), 
3.70–3.75 (d, J=14 Hz, 1 H), 4.27-4.35 (m, 1 H), 505-5.09 
(d, J=12 Hz, 1 H), 5.12 (s, 2 H), 5.21-5.25 (d, J-12 Hz, 1 
H), 5.35-5.39 (d. J=11 Hz, 1H), 6.01 (s, 1H), 6.75-6.78 (m, 
2H), 7.04-7.19 (m, 3 H), 7.31–7.41 (m, 10 H); 'C NMR 
(125 MHz, CDC1) & 38.8, 64.5, 68.0, 68.2, 69.0, 73.9, 
127.7, 128.9, 129.0, 129.1, 1293, 129.33, 129.4, 129.5, 
130.4, 135.1, 135.6, 136.6, 157.8, 171.6; Anal. Calcd for 
CHNO: C, 69.48; H, 6.05; N, 3.11. Found: C, 69.71; H, 
6.10; N, 3.23. (E)-32b (white solid): (230 mg, 21%) mp 
978-99 C.; IR (film)3482-3223, 1716 cm; H NMR (300 
MHz, CDCl)82.19-2.28 (m. 1 H), 3.31-3.36 (d, J-14 Hz, 
1 H), 3.51-3.56 (d, J=14 Hz, 1 H), 3.73-3.81 (m, 2 H), 
3.82-3.90 (m, 1 H), 4.31-439 (m, IH), 4.99-5.03 (d, J-12 
Hz, 1 H), 5.11-5.22 (m, 3 H), 5.65 (s, 1 H), 6.866.89 (m, 2 H), 7.06–7.19 (m, 3 H), 7.30-7.42 (m. 10 H); 'CNMR 
(125MHz 837.8, 62.3, 66.9, 67.1, 68.2, 74.7, 127.2, 128.2, 
128.3, 128.5, 128.6, 128.7, 128.8, 128.82, 129.8, 1346, 
134.8, 136.1, 156.0, 171.3; Anal. Calcd for CHNO6: C, 
69.48; H, 6.05; N, 3.11. Found: C, 69.54; H, 6.04; N, 3.15. 
Benzyl 2-Benzyloxycarbamido-3,4-dihydroxy-2-(2- 
propyl)butanoate (E) 31a/(E)-31b). From (E)-18 (508 mg, 
1.38 mmol), following General Procedure B, were obtained 
two diastereomerically pure products (E)-31a; 103 mg, 
18%; (E)-31b; 159 mg, 29% (63% overall yield based on 
recovered starting material)). (E)-31a: "H NMR (500 MHz, 
CDCl)5 0.74–0.76 (d, J-7 Hz, 3 H), 1.11-1.13 (d, J=7 Hz, 
3 H), 1.81-1.83 (m, 1 H), 2.69 2.74 (app quintet, J-7 Hz, 
1H), 3.29-3.33 (m, 1 H), 3.53-3.57 (dd, J-7 Hz, 1 H), 
4.31-4.36(m, 1 H), 5.03-5.10 (dd, J-12 Hz, 2 H), 5.15-5.23 
(dd, J=12 Hz, 2 H), 5.58-5.60 (d, J-11, 1H), 6.36 (s, 1 H), 
7.30-7.40 (m, 10H), (+)-31 (500 MHz, CDC) 80.85–0.87 
(d, J-7 Hz, 3 H), 0.95-0.97 (d. J=7 Hz, 3 H), 2.45-2.53 (m, 
2H), 3.67-3.73 (m, 2 H), 4.04-4.06 (m, 1 H), 4.39-4.43 (m, 
1H), 5.03-5.10 (dd, J-12 Hz, 2H), 5.17-5.26 (dd, J-12 Hz, 
2 H), 5.61 (s, 1 H), 7.31-7.14 (m, 10 H). 
Benzyl 2-Benzyloxycarbamido-3,4-dihydroxy-2- 
methylbutanoate (E)-30b/Lactone (E)-45a. From 17 (200 
mg 0.589 mmol), following General Procedure B, was 
obtained lactone (E)-45a (52 mg, 24%; apparently derived 
from diol (E)-30a) in a first fraction, and diol (E)-30b (39 
mg, 18%) in a second fraction (70% overall yield based on 
recovered starting material). (+)-30b: "H NMR (500 MHz, 
CDC) 81.57 (s.3 H), 1.6-2.6 (br, 2 H), 3.64-3.68 (dd, J=6, 
12 Hz, 1 H), 3.70–3.73 (dd, J-4, 12 Hz, 1H), 4.00-402 (m, 
1H), 5.04-5.09 (dd, J=12 Hz, 2 H), 5.19 (s, 2 H), 5.75 (s, 
1H), 7.29-7.38 (m. 10 H). (E)-45a: "H NMR (300 MHz, 
CDCl3) 81.44 (s, 3 H), 3.92-3.98 (appt, J=9 Hz, 1 H), 4.46 
(s, 1H), 4.49-4.55 (appt, J-9 Hz, 1 H), 4.65-4.71 (appt. J-9 
Hz, 1 H), 5.06-5.11 (d, J =12Hz, 1H).5.11-5.15(d, J-12 Hz, 
1H), 5.70 (s, 1 H), 7.30-7.41 (m, 5 H). 
General Procedure C 
erythro-Benzyl-2-Benzyl-2-benzyloxycarbamido-3- 
hydroxy-4-mesyloxybutanoate (E)-35a). To a solution of 
(E)-32a (250 mg, 0.56 mmol)in CHCl/pyridine (1:1) at 
-78° C., was slowly added methanesulfonylchloride (43 uL, 
0.56 mmol). The reaction mixture was allowed to warm to 
rt over a period of 2-3 h. The reaction mixture was parti 
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tioned between 1N HCl (75 mL) and EtOAc (100 mL). The 
organic layer was further extracted with NaHCO (aq, sat'd, 
75 mL), then dried (MgSO), filtered and concentrated. 
Purification by SiO, chromatography (50% EtOAchexane) 
gave (E)-35a (237 mg, 81%) as a white solid; mp. 84-86° 
C.; IR (film) 3413-3245,1736,1691 cm '; 'H NMR (500 
MHz, CDCl)852.87 (s.3 H), 3.08-3.11 (d. J=14 Hz, 1H), 
3.68-3.71 (d. J=14 Hz, 1H), 4.00-4.04 (dd, J-7.11 Hz, 1H), 
4.21-4.24(dd, J-6, 11 Hz, 1 H), 4.54-4.59 (m, I H), 
5.07-5.10 (d. J=12 Hz, 1 H), 5.12 (s, 2 H), 5.25-5.27 (d, 
J=12 Hz, 1 H), 5.67-5.70 (d. J=11 Hz, 1 H), 6.05 (s, 1 H), 
6.73-6.75 (m, 2H), 7.06-7.08 (m,2H), 7.15-7.18 (m, 1 H), 
7.33-7.43 (m, 10 H); 'CNMR (125MHz, CDC1,) 837.2, 
38.0, 67.3, 67.9, 68.9, 69.4, 73.3, 127.2, 128.4, 128.5, 128.6, 
128.7, 128.8, 129.0, 129.1, 129.7, 134.1, 1344, 135.6, 
1574, 1702; Anal. Calcd for CHNOS: C, 61.47; H, 
5.54; N, 2.65. Found: C, 61.37; H, 5.71; N, 2.73. 
threo-Benzyl 2-Benzyl-2-benzyloxycarbamido-3- 
hydroxy-4-mesyloxybutanoate (E)-35b). From (E)-32b 
(250 mg, 0.56 mmol), following General Procedure C, was 
obtained (E)-35a (217 mg, 74%) as an oil: IR (film) 
3393-3315, 1735, 1691 cm; H NMR (360 MHz, CDC1) 
8147 (s, 1 H), 2.94 (s, 3 H), 3.38-3.40 (d, J-14 Hz, 1 H), 
3.43-3.48 (d, J-14 Hz, 1 H), 4.32-4.38 (m, 1 H), 4.41-4.44 
(m, 1 H), 4.644.70 (m, 1 H), 5.00-5.21 (m, 4H), 5.53s, 1 
H), 6.83-6.85 (m.2 H), 7.09-7.22 (m, 3 H), 7.31–7.42 (m, 
10 H); Anal. Calcd for CHNOS: C, 61.47; H, 5.54; N, 
2.65. Found: C, 61.27; H, 5.55; N, 2.69. 
erythro-Benzyl 2-Benzyloxycarbamido-3-hydroxy-4- 
mesyloxy-2-(2-propyl)butanoate (E)-34a). From (E)-31a 
(100 mg., 0.25 mmol), following General Procedure C, was 
obtained crude mesylate (E)-34a of sufficient purity to be 
employed directly for the next step (General Procedure D, 
vide infra): "HNMR (300MHz, CDC)5 0.77-0.79 (d, J=7 
Hz, 3 H), 1.12-1.14 (d, J=7 Hz, 3 H), 2.89 (s, 3 H), 
3.93-3.98 (dd, J-7, 11 Hz, 1 H), 4.16.4.22 (dd, J=6, 11 Hz, 
1H), 4.59–4.63 (appt, J=6 Hz, 1H), 5.07-5.12 (d, J=12 Hz, 
1 H), 5.12-5.17 (d, J=12 Hz, 1 H), 5.17-5.25 (d, J-12 Hz, 
1 H), 5.26-5.29 (d, J=12 Hz, 1 H), 6.42 (s, 1 H), 732-7.42 
(m. 10 H). 
threo-Benzyl 2-Benzyloxycarbamido-3-hydroxy-4- 
mesyloxy-2-(2-propyl)butanoate (E)-34b). From (E)-31 b 
(147 mg, 0.37 mmol), following General Procedure C, was 
obtained crude mesylate (E)-34b of sufficient purity to be 
employed directly for the next step (General Procedure D, 
vide infra). 
threo-Benzyl 2-Benzyloxycarbamido-3-hydroxy-4- 
mesyloxy-2-methylbutanoate (E)-33b). From (E)-30b (92 
mg, 0.25 mmol), following General Procedure C, was 
obtained crude mesylate (E)-33b of sufficient purity to be 
employed directly for the next step (General Procedure D, 
vide infra). 
General Procedure D 
erythro-B enzyl N-B enzyloxycarbonyl-ol 
oxiranylphenylalaninate (E)-29a). To a solution of diiso 
propylamine (86 mL, 0.61 mmol) in THF (8 mL) at -78° C. 
was added n-butyllithium (380 ul, 1.6M in n-hexane), and 
the resulting solution stirred for 30 min at 0°C. To the LDA 
solution thereby generated at -78° C. was added via 
cannula, a solution of (+)-35a (293 mg, 0.55 mmol) in THF 
(8 mL). The resulting reaction mixture was allowed to 
slowly warm up to rt, and was then partitioned between 
EtOAc (50 mL) and 1NHCl (50 mL). The organic layer was 
dried (MgSO), filtered and concentrated. Flash chromatog 
raphy (50% EtOAclhexane) provided (E)-29a (173 mg, 
5,705,660 
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72%) as a white solid: mp 90°-92 C.; ER (film)3411-3298, 
1736, 1721cm; H NMR (300 MHz, CDC1)8 2.74-2.76 
(m. 1 H). 2.83-2.86 (m. 1 H), 3.27-3.32 (d. J-13 Hz, 1 H), 
3.45 (s, 1 H), 3.45-3.50 (d. J=13 Hz, 1 H), 5.06–5.10 (d, 
J=12 Hz, 1 H). 5.12-5.16 (d, J=12 Hz, 1 H), 5.19 (s, 2 H). 
5.31(s, 1 H), 6.99-7.01 (m. 2 H), 7.13–7.24 (m, 3 H), 
7.29-7.43 (m. 10 H); CNMR (125 MHz, CDC1) 838.7, 
44.6, 53.6 62.7, 66.8, 67.8, 127.1, 128.20, 128.23, 128.3, 
128.4,128.5 (2 C), 128.6, 130.1, 134.5, 1349,136.2, 1549, 
169.9; Anal. Calcd for CHNO: C, 72.36; H, 5.84; N, 
3.24. Found: C, 72.55; H, 6.07; N, 3.21. 
threo-Benzyl N-Benzyloxycarbonyl-ol 
oxiranylphenylalaninate (E)-29b). From (E)-35b (130 mg, 
0.25 mmol), following General Procedure D, was obtained, 
after chromatography (50% EtOAc/hexane), (E)-29b (75 
mg, 70%): 'H NMR (300 MHz, CDCl3) 82.43–2.48 (m, 1 
H), 2.71-2.76 (m. 1 H), 3.40-345 (m. 1 H), 3.46–3.50 (d, 
s14 Hz, 1 H), 3.643.69 (d. J=14 Hz, 1 H), 5.04-5.08 (d, 
J-12 Hz, IH), 5.11-5.15 (d. J=12 Hz, 1 H), 5.21-5.25 (m, 
2H), 5.32 (s, 1 H), 6.92-6.94 (m.2 H), 7.05-7.24 (m, 3 H). 
7.29-7.42 (m, 10 H);Anal. Calcd for CHNO:C, 
72.36;H, 5.84; N, 3.24. Found: C, 72.17; H, 5.89; N, 3.29. 
erythro-Benzyl N-Benzyloxycarbonyl-o-oxiranylvalinate 
(E)-28a). From crude mesylate (E)-34a, following General 
Procedure D, was obtained (E)-28a (57.5 mg, 44%-2 step 
yield) after chromatography (50% EtOAc/hexane). This 
material displayed identical spectral characteristics to that 
obtained by direct epoxidation (vide supra). 
threo-Benzyl N-Benzyloxycarbonyl-O-oxiranylvalinate 
(E)-28b). From crude mesylate (E)-34b, following General 
Procedure D, was obtained (E)-28b (76.5 mg, 40%-2 step 
yield) after chromatography (50% EtOAc/hexane). This 
material displayed identical spectral characteristics to that 
obtained by direct epoxidation (vide Supra). 
threo-Benzyl N-Benzyloxycarbonyl-ol-oxiranylalaninate 
(E)-27b). From crude mesylate (E)-33b, following General 
Procedure D, was obtained (E)-27b (33.5 mg. 38%-2 step 
yield) after chromatography (50% EtOAc/hexane). This 
material displayed identical spectral characteristics to that 
obtained by direct epoxidation (vide supra). 
(3) THE DEPROTECTION STEP 
In the final step, the protecting groups (Bn or COBn) are 
removed hydrogenolytically to produce the fully 
deprotected, ot-oxiranyl amino acids. There are character 
ized by H NMR in DO and HRMS. 
We have found that hydrogenation of both diastereomeri 
cally homogeneous ot-oxiranylvalines and of both diastereo 
merically homogeneous o-oxiranyl phenylalanines cleanly 
yields the corresponding free ot-oxiranyl amino acids. (See 
Scheme 9, below) 
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-continued 
Scheme 9: Deprotection Step. 
O O 
4 - 4 y. 
(E) Bno M NHCbz si,st (+)-o NH, 
O O 
R = Bin 29a R = Bn 38a (97%) 
29b. 38b (98%) 
(a = erythro; b = threo) 
Comparison of the "H and 'C NMR spectra of these 
compounds with the data reported for flavovirin supports 
this structure assignment. No evidence for cyclization to the 
y-lactones (Baldwin-disfavored) or to the B-lactones is seen. 
The stability of one o-oxiranyl amino acid 
(o-oxiranylvaline; threo diastereomer) was also studied as a 
function of pH. Interestingly, this ot-oxiranyl amino acid is 
(i) completely stable in DO for at least one month; (ii) 
completely stable at pH 3 (DCL/100 mM NaPO, buffer) for 
one week; and (iii) stable to pH 12.6 (100 mM NaPO buffer) for several days, as judged by "H NMR. 
SPECIFIC EXAMPLES OF THE 
DEPROTECTION STEP 
General Procedure E 
erythro-O-Oxiranylvaline (E)-37a). A solution of (E)-28a 
(50 mg, 0.13 mmol) in CH-OH (5 mL) containing 20% 
Pd(OH) on carbon (7 mg) was stirred, under H. 
atmosphere, at rt for 45 min to give (E)-37a (21 mg, 98%): 
"H NMR (300 MHz, DO) 8 1.02-1.04 (d, J =7 Hz, 3 H), 
1.1.0-1.13 (d, J-7 Hz, 3 H), 2.46-2.51 (app quintet, J-7 Hz, 
1H), 2.87–2.89 (app t, J=3 Hz, 1H), 2.94-2.96 (app t, J-4 
Hz, 1 H), 3.51-3.53 (dd, J=34 Hz, 1 H); "C NMR(125 
MHz, DO) 8 16.5, 17.3, 34.4, 44.2, 54.4, 67.1, 173.7; 
HRMS (FAB, 3-NOBA) calcd for CHNO (M--H) 
160.0974, obsd 160.0970. 
threo-o-Oxiranylvaline (E)-37b). From (E)-28b (100 mg 
0.261 mmol), following General Procedure E, was obtained (+)-37b (41.1 mg, 99%): "H NMR (500 MHz, DO) 8 
1.04-1.06 (d, J=7 Hz, 3 H), 1.07-1.09 (d, J-7 Hz, 3 H). 
2.43-2.46 (app quintet, J=7 Hz, 1H), 2.92–2.93 (app t, J=3 
Hz, 1H), 3.11-3.13 (appt, J=4 Hz, 1H), 3.64-3.66(dd, J-3, 
4 Hz, 1 H); "C NMR (125 MHz, DO)8 16.7, 17.4, 32.2, 
45.8, 54.9, 67.6, 174.0; HRMS (FAB, 3-NOBA) calcd for 
CHNO (M+H)" 160.0974, obsd 160,0974. 
erythro-O-Oxiranylphenylalanine (E)-38a). From (E)- 
29a (50 mg, 0.12 mmol), following General Procedure E, 
was obtained (E)-38a (24 mg, 100%): "H NMR (500 MHz, 
DO) 83.00-3.03 (appt, J-4 Hz, 1 H).3.04-3.06 (appt, J=3 
Hz, 1 H), 3.21-3.26 (d, J = 14 Hz, 1 H), 3.46–3.51 (d, J-14 
Hz, 1 H), 3.56-3.59dd, J-3, 4 Hz, 1H), 7.31-7.34 (m, 2 H), 
7.40-7.45 (m, 3 H); CNMR (75 MHz, DO)540.5, 45.3, 
54.6, 69.5, 128.7, 129.8, 130.8, 133.8, 174.1. 
threo-o-Oxiranylphenylalanine (E)-38b). From (E)-29b 
(27 mg, 63 mol), following General Procedure E, was 
obtained (+)-38b (13 mg, 100%): "HNMR (500MHz, DO) 
82.92-2.94 (app t, J-3 Hz, 1 H), 3.01-3.05 (d, J-14 Hz, 1 
H), 3.04-3.07 (app t, J–4 Hz, 1 H), 3.32-3.37 (d, J=14 Hz, 
1 H), 3.643.67 (dd, J=3, 4 Hz, 1 H), 7.26–7.29 (m, 2 H), 
7.37-7.42 (m, 3 H); 'CNMR (125MHz, DO)838.2, 45.8, 
55.0, 64.9, 128.9, 129.9, 1310, 133.8, 171.4. 
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etythro-8-Oxiranylalanine (E)-36a). From (E)-27a (50 
mg, 0.14 mmol), following General Procedure E, was 
obtained (E)-38a (18 mg.98%): NMR (300 MHz, DO) 8 
1.60 (s.3 H). 2.96-3.01 (m, 2 H), 3.42-3.45 (dd, J-34 Hz, 
1 H); C NMR (75 MHz, DO)8 20.2, 45.7, 55.0, 63.4, 
1745. 
Thus, we have established (i) an efficient synthesis of 
o-vinyl amino acids from the parent amino acids; and (ii) 
two independent routes from these to the targeto-oxiranyl 
amino acids. Taken together, this work has established a 
straightforward procedure for transforming a given amino 
acid into two diastereomerically homogeneous threo and 
erythro O-oxiranyl amino acids. 
(4) DETERMINATION OF THE RELATIVE 
STEREOCHEMISTRY 
The relative stereochemistry of each of the ot-oxiranyl 
amino acids synthesized could be deduced from cyclization 
experiments performed on the protected vicinal diols pro 
duced in the osmylation step. Thus, treatment of diols 31a 
and 32a with Nail in DMF yielded the bicyclic oxazolidi 
nones 4.0a and 41a, respectively (see Scheme 10, below). 
Two cyclizations had occurred, leading to the formation of 
both a 8-lactone and an oxazolidinone ring, in a 5.5-cis 
fusion, with the release of two molecules of benzyl alcohol. 
On the other hand, treatment of the diastereomeric diols 31 
b and 32b with NaH in DMF produced the monocyclic 
lactones 43b and 44b, with the release of one molecule of 
benzyl alcohol. In the alanine series, at the dihydroxylation 
step, the slower-eluting(threo) diol 30b was isolated, but the 
faster-eluting (erythro) diol was obtained in monocyclized 
form, as the corresponding 6-lactone 45a. Treatment of 45a 
with Nail in DMF produced the bicyclic oxazolidinone 39a, 
whereas 30b produced only moncyclic 8-lactone 42b, under 
the same conditions. 
Scheme 10: Determination of Relative Stereochemistry: erythrows threo 
erythro 
O 
H OH 
NaH HN 
(E) BnOCHN OH SG) (t) R. H 
R. C. OB O O 
R = Me 45a (lactone) Re Me 39a 
Re-Pr 31a RE-Pr 40a 
Rae Bill 32a Ric Bn. 41a. 
threo 
OHH BnOCHN H 
s NaH. (t) Bno-CHN OH SG) (E) R. OH 
R. C O2Bn O O 
Ric Me 30 R = Me 42b 
R= -Pr 31b. Rei-Pir 43b 
Ric Bn 32b R = Bn. 44b 
(a = erythro; b. = threo) 
One can deduce from these experiments that the a series 
compounds have the erythro relative stereochemistry which 
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permits the formation of the 5.5-cis fused oxazolidinonellac 
tones 39a-41a. The b series compounds, on the other hand, 
must possess the threo relative stereochemistry as bicyclic 
oxazolidinonelactones are not formed here, because these 
would necessarily be highly strained, 5,5-transfused sys 
tems. Therefore, one observes only a single cyclization to 
the monocyclic 8-lactones 42b-44b, in these cases. On the 
basis of these results, the relative stereochemistry of each of 
the ot-oxiranyl amino acids synthesized can also be deduced, 
as these have been chemically correlated with the corre 
sponding vicinal diols (see Scheme 8, above). 
SPECIFIC EXAMPLES OF THE CYCLIZATION 
STEP 
(TO DETERMINE RELATIVE 
STEREOCHEMISTRY) 
General Procedure F 
()-erythro-Oxazolidinone 41a. To a solution of (+)-32a 
(25 mg, 0.056 mmol) in DMF (1 mL) at 0°C. was added 
NaH (0.1 mg, 60% dispersion in mineral oil). The reaction 
mixture was slowly allowed to warm to rt, then quenched 
with 1NHCl (5 mL)/CHCl (25 mL). The organic layer was 
dried (MgSO), filtered and concentrated to yield (E)-41a (6.7 mg, 52%): 'HNMR (500 MHz, CDC) & 3.07-3.10 (d. 
J=13 Hz, 1H), 3.40-3.43 (d, J-13 Hz, 1 H), 3.56-3.59 (did, 
J-5, 11 Hz, 1 H), 4.32-4.35 (d, J-11 Hz, 1H), 5.00-5.02 (d, 
J=5 Hz, 1 H), 5.65 (s, 1 H), 7.19-7.21 (m, 2 H), 7.35-7.38 
(m, 3 H). 
(E)-threo-Lactone 44b. From (E)-32b, following General 
Procedure F, was obtained (E)-44b: "H NMR (360 MHz, 
CDC1) 83.03–3.05 (d, J=13 Hz, 1 H), 3.29-3.31 (d, J-13 
Hz, 1 H), 3.83-3.92 (app t, J-9 Hz, 1 H), 4.41-4.50 (app t, 
J=9 Hz, 1 H), 4.61-4.62 (s, 1 H), 4.74-4.80 (m, 1 H), 
5.05-5.07 (d, J-13 Hz, 1 H), 5.21-5.23 (d, J-13 Hz, 1 H), 
5.48 (s, 1 H), 7.01-7.04 (m. 2 H), 7.21-7.38 (m, 3 H). 
(E)-erythro-Oxazolidinone 40a. From (E)-31a, following 
General Procedure F, was obtained (E)-40a: "H NMR (500 
MHz, CDC1) 81.03-1.05 (d, J-7 Hz, 3 H), 1.05-107 (d, 
J=7 Hz, 3 H). 2.51-2.74 (app quintet, J=7 Hz, 1 H), 
4.064.10 (app t, J-9 Hz, 1H), 4.18-4.19 (d, J-2 Hz, 1 H), 
4.484.52 (app t, J-9 Hz, 1 H), 4.83-487. (m, 1 H), 
5.08-5.11 (m, 2 H), 5.69 (s, 1 H), 7.28–7.39 (m, 5 H). 
(E)-threo-Lactone 43b. From (E)-31 b, following General 
Procedure F, was obtained (E)-43 b: "H NMR (500 MHz, 
CDC) 80.99-1.01 (d, J-7 Hz, 3 H), 1.07-109 (d, J-7 Hz, 
3 H). 2.25-2.30 (quintet, J-7 Hz, 1 H), 4.43-4.47 (dd, J-5, 
11 Hz, 1 H), 4.56-4.59 (d, J-11 Hz, 1 H), 4.95-497 (d, J-5 
Hz, 1 H), 5.53 (s, 1 H). 
(E)-erythro-Oxazolidinone 39a. From (E)-45a, following 
General Procedure F, was obtained (E)-39a: "H NMR 
(300MHz, CDCL)8 1.48 (s, 3 H), 3.02 (s, 1 H), 4.39-457 
(m, 3 H), 5.12 (s, 2 H), 5.46 (s, 1 H), 7.33-7.39 (m, 5 H). 
(E)-threo-Lactone 42b. From (E)-30b, following General 
Procedure F, was obtained (E)-42b: "H NMR (360 MHz, 
CDC1) 8 1.43 (s, 3 H), 3.96-3.99 (m. 1 H), 4.12-4.16 (m, 
1 H), 4.52-4.56 (m, 1 H), 4.77-4.81 (m, 1 H), 5.36 (s, 1 H). 
We claim: 
1. A method of synthesizing O-oxiranyl amino acids, 
comprising: 
(a) adding protective groups to the amino and carboxyl 
groups and to any hydroxyl and amino groups on side 
chains of ano-vinyl amino acid by heating saido-vinyl 
amino acids with benzyl chloroformate in dimethylsul 
foxide in the presence of triethylamine and catalytic 
4-dimethylaminopyridine; 
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(b) extracting and purifying the protected o-vinyl amino 
acid; 
(c) converting the O-vinyl group of the protected O-vinyl 
amino acid obtained in step (b) to an o-oxiranyl group 
by epoxidation: and 
(d) removing the protecting groups. 
2. The method of claim 1 wherein saido-vinyl amino acid 
is heated to approximately 50° C. with benzyl chloroformate 
in dimethylsulfoxide in the presence of triethylamine and 
catalytic 4-dimethylaminopyridine. 
3. The method of claim 2 wherein said mixture is heated 
for approximately 1.5 hours. 
4. The method of claim 1 wherein said epoxidation is a 
direct epoxidation. 
5. The method of claim 4 wherein said direct epoxidation 
comprises mixing said protected amino acid with meta 
chloroperoxybenzoic acid. 
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6. The method of claim 1 wherein said epoxidation is an 
indirect epoxidation. 
7. The method of claim 6 wherein said indirect epoxida 
tion comprises the steps of first converting the vinyl group 
to the diastereomeric erythro and threo vicinal diols through 
the agency of osmium tetroxide, and then separating the 
erythro and threo diastereomers by silica gel chromatogra 
phy and then transforming these diastereomers individually 
to the respective epoxide by regiospecific mesylation of the 
less hindered primary hydroxyl group using methanesulfo 
nyl chloride in pyridine-dichloromethane followed by treat 
ment with lithium diisopropylamide in tetrahydrofuran to 
give the diastereomerically homogenous epoxide. 
8. The method of claim 1 wherein said protected groups 
are removed by hydrogenation in the presence of a palla 
dium catalyst, 
